Journal: Frontiers in bioscience (Landmark edition)

Article Title: MiR-145 Alleviates Sepsis-Induced Inflammatory Responses and Organ Injury by Targeting ADAM17.

doi: 10.31083/j.fbl2901044

Figure Lengend Snippet: Fig. 1. Lipopolysaccharide (LPS) reduces miR-145 expression, overexpression of miR-145 downregulated ADAM17 expression

Article Snippet: The membranes were incubated with antibodies against ADAM17 (sc-390859, mouse monoclonal antibody, 1:800, Santa Cruz Biotechnology, Santa Cruz, CA, USA; A00604, rabbit polyclonal antibody, 1:800, Boster Biological Technology, China) or β-actin (sc-47778, mouse monoclonal antibody, 1:4000, Santa Cruz Biotechnology, USA) at 4 °C overnight.

Techniques: Expressing, Over Expression

Journal: Frontiers in bioscience (Landmark edition)

Article Title: MiR-145 Alleviates Sepsis-Induced Inflammatory Responses and Organ Injury by Targeting ADAM17.

doi: 10.31083/j.fbl2901044

Figure Lengend Snippet: Fig. 2. miR-145 alleviated LPS-induced endothelial inflammation by targeting ADAM17 in HUVECs. HUVECs were infected by LV-NC, LV-miR-145, LV-ADAM17-siRNA or the combined of LV-miR-145 and LV-ADAM17-siRNA. (A) Green fluorescence protein

Article Snippet: The membranes were incubated with antibodies against ADAM17 (sc-390859, mouse monoclonal antibody, 1:800, Santa Cruz Biotechnology, Santa Cruz, CA, USA; A00604, rabbit polyclonal antibody, 1:800, Boster Biological Technology, China) or β-actin (sc-47778, mouse monoclonal antibody, 1:4000, Santa Cruz Biotechnology, USA) at 4 °C overnight.

Techniques: Infection, Fluorescence

Journal: Frontiers in bioscience (Landmark edition)

Article Title: MiR-145 Alleviates Sepsis-Induced Inflammatory Responses and Organ Injury by Targeting ADAM17.

doi: 10.31083/j.fbl2901044

Figure Lengend Snippet: Fig. 3. Overexpression of miR-145 reduces expression of ADAM17, attenuates sepsis-induced inflammatory responses and acute lung injury. (A) Schematic of experimental design and time line. Polymicrobial sepsis model of mice was induced in C57BL/6 mice

Article Snippet: The membranes were incubated with antibodies against ADAM17 (sc-390859, mouse monoclonal antibody, 1:800, Santa Cruz Biotechnology, Santa Cruz, CA, USA; A00604, rabbit polyclonal antibody, 1:800, Boster Biological Technology, China) or β-actin (sc-47778, mouse monoclonal antibody, 1:4000, Santa Cruz Biotechnology, USA) at 4 °C overnight.

Techniques: Over Expression, Expressing

Journal: Frontiers in bioscience (Landmark edition)

Article Title: MiR-145 Alleviates Sepsis-Induced Inflammatory Responses and Organ Injury by Targeting ADAM17.

doi: 10.31083/j.fbl2901044

Figure Lengend Snippet: Fig. 4. MiR-145 agomir reduces expression of ADAM17, attenuates sepsis-induced acute kidney injury and offers survival benefit.

Article Snippet: The membranes were incubated with antibodies against ADAM17 (sc-390859, mouse monoclonal antibody, 1:800, Santa Cruz Biotechnology, Santa Cruz, CA, USA; A00604, rabbit polyclonal antibody, 1:800, Boster Biological Technology, China) or β-actin (sc-47778, mouse monoclonal antibody, 1:4000, Santa Cruz Biotechnology, USA) at 4 °C overnight.

Techniques: Expressing

Journal: British Journal of Pharmacology

Article Title: Monoclonal antibodies against metzincin targets

doi: 10.1111/bph.14186

Figure Lengend Snippet: Properties of mAbs developed against metzincin targets

Article Snippet: Another anti‐ADAM17 antibody was developed by MedImmune, LLC.

Techniques: Concentration Assay, In Vitro, Ex Vivo, In Vivo, Activity Assay, Inhibition, Activation Assay, Lysis

Journal: Oncoimmunology

Article Title: Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells

doi: 10.1080/2162402X.2017.1364827

Figure Lengend Snippet: ADAM10 and ADAM17 expression in thrombopoietic cells. (A) CD34+ haematopoietic progenitor cells were cultured for 12 d in the presence of thrombopoietin to induce megakaryocyte differentiation. On days 0, 6, 9, and 12 mRNA expression of ADAM10 and ADAM17 was analyzed by qPCR. Representative data of one from a total of 3 biologic experiments performed in technical replicates are shown. (B) Platelets from healthy donors were either left untreated (resting) or activated with ADP, collagen or thrombin until aggregation was visible (for a maximum of 30 s to prevent clumping) as described previously.23 Then FACS analysis of ADAM10 or ADAM17 expression was performed. (C) Platelets were either left untreated (resting) or activated by exposure to the platelet superagonist TRAP-6 (5 µM) for 5 minutes. Then ADAM10 and ADAM17 levels in platelet pellets and releasate was analyzed by Western blot. In (B-C), representative data of one experiment from a total of at least 4 with similar results are shown. (D) Resting platelets from healthy donors and patients with NSCLC were analyzed by FACS as described in (B). Statistically significant differences (p<0.05, Kolmogorov-Smirnov test) are indicated by *.

Article Snippet: Membrane was blocked for 1 h at room temperature with Roti-Block, followed by overnight incubation at 4°C with anti-ADAM10 or anti-ADAM17 antibody (1:1000 each; Cell Signaling Technologies and Triple Point Biologics, respectively).

Techniques: Expressing, Cell Culture, Western Blot